There are 437 resources available
1477P - STK11 mutations predict poor prognosis for advanced NSCLC treated with first-line immunotherapy or chemo-immunotherapy according to KRAS, TP53, KEAP1, and SMARCA4 status
Presenter: Andrea De Giglio
Session: Poster session 21
25P - Role of AXL activation on adaptive resistance to KRAS-G12C inhibitors in KRAS-G12C-mutated non-small cell lung cancer
Presenter: Tadaaki Yamada
Session: Poster session 09
Welcome and introduction
Presenter: Enriqueta Felip
Session: ESMO Colloquium supported by Daiichi Sankyo, Europe in collaboration with AstraZeneca: The impact of antibody-drug conjugates (ADCs) in the changing treatment landscape of advanced NSCLC
Resources:
Slides
Webcast
Introduction and scientific background
Presenter: Raffaele Califano
Session: Open questions in immunotherapy for advanced NSCLC: Duration of IO, combinations and rechallenge
Resources:
Slides
Webcast
1843MO - The effect of chronic psychological stress on the efficacy of first-line therapy of ICIs in advanced NSCLC (STRESS-LUNG-1 trial)
Presenter: Fang Wu
Session: Mini oral session - Supportive and palliative care
Resources:
Abstract
Slides
Webcast
2209P - Mutational status of non-small cell lung cancer in Portugal: A multicentric study
Presenter: Joana Duarte
Session: Poster session 07
1364P - ctDNA analysis of SAF-189s efficacy in ALK+ advanced non-small cell lung cancer (NSCLC)
Presenter: Jin-Ji Yang
Session: Poster session 19
1368P - LUMINATE 102: A real-world study on biomarker testing rates among patients with non-small cell lung cancer (NSCLC) across lines of therapy
Presenter: Charu Aggarwal
Session: Poster session 20
1330P - Updated results of the efficacy and safety of KN046 (a bispecific anti-PD-L1/CTLA-4) in patients with metastatic non-small cell lung cancer (NSCLC) who failed prior EGFR-TKI(s)
Presenter: Caicun Zhou
Session: Poster session 19